Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 102Carcinoma, Non-Small-Cell Lung 84Glioblastoma 77Brain Neoplasms 75Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 51Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Melanoma 35Ovarian Neoplasms 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

Specimen Handling 3Nivolumab 3olaparib 2durvalumab 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2temsirolimus 1sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1defactinib 1copanlisib 1ceralasertib 1cediranib 1capivasertib 1cabozantinib 1adavosertib 1Therapeutics 1Taxes 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1RO5126766 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × Magnetic Resonance Spectroscopy × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡